Cell-Free Nucleic Acid TMB Normalization Using Minor Allele Fractions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer detection methods using cell-free nucleic acids in bodily fluids face challenges due to low and variable nucleic acid amounts, complicating the assessment of tumor mutation burden (TMB), which is crucial for predicting responsiveness to immunotherapy.
Innovation Solution
A method to normalize TMB by determining mutations in cell-free nucleic acids, using a minor allele fraction, and comparing them to control samples within a bin of similar fractions, calculating a Z-score to standardize the measurement, facilitating the administration of immunotherapy based on standardized TMB thresholds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If cell-free nucleic acid tests are used for cancer detection, then non-invasive detection is achieved, but measurement precision of tumor mutation burden is reduced due to low and variable nucleic acid amounts
Solution Approach 1:
The patent transforms the raw mutation count into a normalized TMB score by changing the parameter representation. It uses minor allele fraction as a normalization parameter and applies statistical transformations (Z-scores, percentiles) to convert absolute mutation counts into relative measures that account for variability in nucleic acid input amounts.
Solution Approach 2:
The patent introduces control samples as an intermediary reference system. By comparing test samples against control samples with known characteristics, the method mediates the measurement process to account for technical variations. The control samples serve as a bridge between the variable test conditions and the standardized TMB metric.
2Device complexity
If raw mutation counts are used without normalization, then simplicity is maintained, but reliability of TMB assessment is reduced due to variability in nucleic acid release and recovery
Solution Approach 1:
The patent changes the parameter from raw mutation count to normalized TMB score by incorporating minor allele fraction and statistical normalization. This transforms an absolute measure into a relative measure that is invariant to input variability, thereby improving reliability without requiring complex additional measurements.
Solution Approach 2:
The method uses control samples with known TMB values to establish expected ranges and variability. This feedback mechanism allows the system to adjust and interpret test results in context, comparing observed values against established benchmarks to account for technical variations in nucleic acid extraction and processing.
3Quantity of substance
If TMB measurement is performed on cell-free nucleic acids with low concentration, then non-invasive sampling is enabled, but measurement precision deteriorates due to limited analyte amount
Solution Approach 1:
The patent changes the measurement parameter from absolute mutation count to normalized TMB score. By using minor allele fraction as a denominator and applying statistical normalization, the method makes the measurement precision independent of the absolute nucleic acid quantity, allowing accurate TMB assessment even from low-concentration cell-free DNA samples.
Data Source
AI summary
Values for tumor mutation burden from different samples can be made more comparable to each other or control standards by a normalization regime that takes into account the minor allele fraction of highly rated mutations in a sample. Such analysis can provide an indication where the tumor mutation burden of a test sample lies on a distribution of tumor mutation burdens in a control population, and thus, whether the individual providing the test sample is likely to be amenable to immunotherapy to treat cancer.